title: NF-κB in colorectal cancer.
abstract: Colorectal cancer (CRC) is a leading cause of morbidity and mortality worldwide, responsible for more than half a million deaths annually. CRC is a multistep process that entails the accumulation of genetic/epigenetic aberrations, which lead to the simultaneous failure of protective mechanisms and the activation of tumorigenic pathways. In most cases of CRC a deregulation of the Wnt-signaling pathway is required. The transcription factor nuclear factor κB (NF-κB) has been recognized as a key player in the initiation and propagation of CRC. Under physiological conditions, NF-κB orchestrates the inflammatory process and participates in the modulation of various steps of cell cycle and survival. It is normally kept in an inactive state in the cytoplasm by binding to a group of inhibitory proteins. Upon receipt of a signal, its inhibitor is phosphorylated and proteolytically degraded and NF-κB is actively translocated to the nucleus, where it facilitates target-gene transcription. Recent experimental data reveal the important role of NF-κB in tumor cells as well as in the surrounding "cancerous" and reactive microenvironment. Various tumor cell-derived and contextual cues feed constantly this vicious circuitry sustaining inflammation and promoting proliferation, angiogenesis, invasion and eventually metastasis. Therefore NF-κB along with its upstream and downstream network presents a rational target for therapeutic interventions. Numerous small molecules, inhibitory peptides, antisense RNAs, natural compounds, as well as gene therapy strategies interfere with multiple steps of the NF-κΒ signaling cascade. The design of NF-κΒ-targeted treatment may aid the efforts towards the pursuit of more efficient therapeutic measures devoid of severe systemic side-effects.
authors: Department of Biological Chemistry, University of Athens Medical School, 11527, Athens, Greece.
authors: Aristeidis G
authors: AG
authors: Vaiopoulos
authors: Kalliopi Ch
authors: KCh
authors: Athanasoula
authors: Athanasios G
authors: AG
authors: Papavassiliou
mesh_terms: D000818:Animals; D063646:Carcinogenesis / Q000378:metabolism; D015179:Colorectal Neoplasms / Q000378:metabolism*; D006801:Humans; D016328:NF-kappa B / Q000378:metabolism*
chemical_list: D016328:NF-kappa B
references: Pharmacol Rep. 2007 Mar-Apr;59(2):233-7
references: 17556802
references: Eur J Pharm Sci. 2012 Apr 11;45(5):581-91
references: 22227305
references: Clin Cancer Res. 2012 Sep 15;18(18):4942-53
references: 22832932
references: FEBS J. 2012 Aug;279(16):2966-86
references: 22742445
references: J Gastroenterol Hepatol. 2012 Jan;27(1):39-50
references: 22188027
references: Cancer Biol Ther. 2011 Jul 15;12(2):95-105
references: 21623164
references: Cancer Biol Ther. 2011 Aug 1;12(3):239-51
references: 21725213
references: Tumour Biol. 2012 Dec;33(6):1951-72
references: 23011889
references: Biochem Biophys Res Commun. 2009 Dec 4;390(1):60-4
references: 19778522
references: Oncol Rep. 2012 May;27(5):1527-34
references: 22327383
references: Nat Rev Cancer. 2010 Aug;10(8):561-74
references: 20651737
references: Br J Cancer. 2009 Jul 7;101(1):106-15
references: 19513071
references: Carcinogenesis. 2012 Jun;33(6):1158-68
references: 22461522
references: Cancer Biol Ther. 2011 Jul 1;12(1):59-68
references: 21532339
references: Cancer Lett. 2011 Dec 27;313(2):167-80
references: 21963225
references: Discov Med. 2011 Aug;12(63):97-105
references: 21878187
references: Curr Gene Ther. 2009 Jun;9(3):160-70
references: 19519361
references: Invest New Drugs. 2011 Dec;29(6):1475-81
references: 20574790
references: BMC Cell Biol. 2011 Apr 12;12:14
references: 21486470
references: Ann Rheum Dis. 2011 Mar;70 Suppl 1:i104-8
references: 21339211
references: Dig Dis Sci. 2012 Nov;57(11):2873-82
references: 22623043
references: Stem Cells. 2012 Mar;30(3):363-71
references: 22232074
references: Immunol Rev. 2012 Mar;246(1):346-58
references: 22435565
references: Oncogene. 2011 Apr 7;30(14):1615-30
references: 21170083
references: Cancer Sci. 2010 Jun;101(6):1557-61
references: 20398057
references: Mol Med Rep. 2011 Nov-Dec;4(6):1083-8
references: 21822539
references: Biosci Rep. 2012 Feb;32(1):1-15
references: 21981137
references: Nat Rev Cancer. 2012 Jan 19;12(2):121-32
references: 22257950
references: Am J Cancer Res. 2011;1(2):192-221
references: 21969033
references: PLoS One. 2013;8(2):e57218
references: 23451189
references: Clin Cancer Res. 2011 Sep 1;17(17):5686-94
references: 21771876
references: Nat Immunol. 2011 Jul 19;12(8):689-94
references: 21772277
references: Invest New Drugs. 2011 Apr;29(2):207-24
references: 19876598
references: Proc Natl Acad Sci U S A. 2012 Aug 28;109(35):14007-12
references: 22893683
references: J Biol Chem. 2008 Feb 15;283(7):4094-104
references: 18084005
references: Dig Dis Sci. 2012 Sep;57(9):2325-33
references: 22526587
references: Curr Top Microbiol Immunol. 2011;349:245-63
references: 21113699
references: Curr Cancer Drug Targets. 2011 May;11(4):451-64
references: 21247378
references: Curr Cancer Drug Targets. 2011 Mar;11(3):239-53
references: 21247388
references: CA Cancer J Clin. 2011 Mar-Apr;61(2):69-90
references: 21296855
references: Int J Cancer. 2012 May 1;130(9):2176-84
references: 21702037
references: Br J Cancer. 2010 Feb 16;102(4):639-44
references: 20087353
references: Immunity. 2012 May 25;36(5):742-54
references: 22503542
references: Biochem Pharmacol. 2006 Feb 28;71(5):634-45
references: 16360644
references: Oncology. 2010;78(3-4):181-8
references: 20414006
references: J Gastroenterol. 2009;44(9):935-43
references: 19557302
references: Cancer Discov. 2011 Nov;1(6):469-71
references: 22586649
references: Neoplasia. 2012 Dec;14(12):1097-101
references: 23308042
references: Biochim Biophys Acta. 2011 Jan;1815(1):90-103
references: 20951769
references: EMBO Rep. 2009 Dec;10(12):1314-9
references: 19893576
references: Nat Immunol. 2011 Jul 19;12(8):715-23
references: 21772280
references: Breast Cancer Res. 2012 Jan 06;14(1):R2
references: 22225778
references: Gastroenterology. 2010 Jun;138(6):2101-2114.e5
references: 20420949
references: Mol Cancer Res. 2011 Jan;9(1):14-24
references: 21123622
references: Int J Colorectal Dis. 2007 Jan;22(1):57-68
references: 16506021
references: Int J Cancer. 2010 Jul 1;127(1):195-206
references: 19904749
references: Biomed Pharmacother. 2012 Feb;66(1):12-20
references: 22265104
references: J Clin Invest. 2012 Apr;122(4):1519-28
references: 22406536
references: Chem Biol Interact. 2010 Oct 6;188(1):75-85
references: 20540935
references: J Exp Med. 2011 Aug 29;208(9):1889-900
references: 21825016
references: Biochem Biophys Res Commun. 2012 Sep 7;425(4):781-7
references: 22884800
references: Cancer Cell. 2013 Jan 14;23(1):93-106
references: 23273920
references: Semin Immunopathol. 2013 Mar;35(2):229-44
references: 23161445
references: J Clin Invest. 2011 Jul;121(7):2781-93
references: 21701067
references: Int J Biochem Cell Biol. 2010 Jul;42(7):1061-5
references: 20348011
references: Exp Ther Med. 2012 Oct;4(4):716-722
references: 23170132
references: Cell. 2013 Jan 17;152(1-2):25-38
references: 23273993
references: Mol Cell Biochem. 2010 Mar;336(1-2):25-37
references: 19823771
references: Phytother Res. 2010 Jul;24(7):949-63
references: 20577970
references: Cytokine Growth Factor Rev. 2010 Feb;21(1):11-9
references: 20018552
references: Cell. 2010 Mar 19;140(6):883-99
references: 20303878
references: Ann Rheum Dis. 2013 Apr;72 Suppl 2:ii100-3
references: 23253923
references: Cell Biochem Funct. 2013 Apr;31(3):263-8
references: 23086737
references: BMC Cancer. 2011 Jul 01;11:285
references: 21722370
references: Oncogene. 2012 May 31;31(22):2761-72
references: 21963853
references: J Clin Invest. 2011 Jul;121(7):2551-3
references: 21701071
references: Immunol Rev. 2012 Mar;246(1):59-76
references: 22435547